Prognostic value from integrative analysis of transcription factors c-Jun and Fra-1 in oral squamous cell carcinoma: a multicenter cohort study

Hao Xu[1,2,3#], Xin Jin[4,2#], Yao Yuan[2], Peng Deng[2], Lu Jiang[2], Xin Zeng[2], Xiao-Song Li[1], Zhi-Yong Wang[2*], Qian-Ming Chen[1,2*].

[1] Department of epidemiology and health statistics, West China School of Public Health, Sichuan University, Chengdu 610041, China;

[2] Department of Oral Biology and Medicine, State Key Laboratory of Oral Diseases, West China School of Stomatology, Sichuan University, Chengdu 610041, China;

[3] School of Mathematics, Sichuan University, Chengdu 610041, China;

[4] Chongqing Key Laboratory of Oral Diseases and Biomedical Sciences, College of Stomatology, Chongqing Medical University, Chongqing 400016, China.

 # These authors contributed equally to this work

* Corresponding author:

Qian-Ming Chen, Department of epidemiology and health statistics, West China School of Public Health, Sichuan University, 16 South Renmin Road, Chengdu 610041, China; Fax & Phone: +86 28 85405251; E-mail: qmchen@scu.edu.cn.

Zhi-Yong Wang, Department of Oral Biology and Medicine, State Key Laboratory of Oral Diseases, West China School of Stomatology, Sichuan University, 14 South Renmin Road, Chengdu 610041, China; Phone: +1 3019066811; E-mail: zhiyong.wang@scu.edu.cn.

Titles and legends for Supplementary Figures

Supplementary Figure S1. The original immunohistochemical staining of patients' tissue from the West China Hospital of Stomatology (Chengdu, China)
A. The immunohistochemical staining of c-Jun.
B. The immunohistochemical staining of Fra-1

Supplementary Figure S2. The survival curves of OSCC patients with different expressions of c-Jun and Fra-1 in different tumor clinical TNM stages
The four images above were from c-Jun's (A, B, C, D) and the below were from Fra-1 (E, F, G, H). From left to right, they were stage 1 (A, E), stage 2 (B, F), stage 3 (C, G) and stage 4 (D, H), separately. The P values were from the log-rank tests for the overall survival.

Supplementary Figure S3. Interaction effects between c-Jun and Fra-1 during each clinical TNM stage
The points are the adjusted Hazzard Ratios (*HRs*), and the error bars are the 95% *CI*. The *HR* were from the interaction factors of c-Jun and Fra-1 in the multiple Cox models. The adjusted *HRs* (95%*CIs; P* values) are as followed: stage 1:172037(0, Inf.; P:0.9991); stage 2:0.1098 (0.0251, 0.4810; P:0.0034), stage 3:0.4056 (0.1164, 1.4140; P:0.1567), stage 4:1.1467 (0.0477, 27.5850; P:0.9328).

Supplementary Figure S1.

Supplementary Figure S2.

Supplementary Figure S3.